These include: Neurological symptoms : tingling or numbness in hands and feet (paraesthesia), difficulty walking, balance problems, memory difficulties, or mood changes Haematological signs : ongoing fatigue, weakness, pale skin, or shortness of breath suggesting anaemia hasn't resolved Glossitis : a sore, red tongue that hasn't improved Cognitive issues : continued difficulty concentrating or memory problems These symptoms, particularly progressive neurological deficits or severe anaemia with cardiorespiratory compromise, may require urgent medical attention
Standard Dosing Ranges Community consensus and research protocols typically use doses ranging from 0.2 to 0.8 mg daily for musculoskeletal applications
Verified Pharmacy Network: We coordinate with licensed 503A and 503B compounding pharmacies and authorized wholesale partners that operate in accordance with applicable USP standards and current regulatory requirements
First, phase II clinical trials evaluating MOTS-c in type 2 diabetes and sarcopenia are in development, and their results will provide the first randomized controlled evidence in humans to define therapeutic doses with statistical rigor
